United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - debrisoquine sulfate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

cambridge laboratories ltd - debrisoquine sulfate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - debrisoquine sulfate - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

eon labs, inc. - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine sulfate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgement of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures (e.g.,

United States - English - NLM (National Library of Medicine)

epic pharma, llc - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see dosage and administration), then quinidine sulfate should be discontinued. chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgement of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. in most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are lifethreatening. because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. where possible, therapy should be guided by the results of programmed electrical stimulation and/or holter monitoring with exercise. antiarrhythmic drugs (including quinidine sulfate) have not been shown to enhance survival in patients with ventricular arrhythmias. quinidine sulfate is also indicated in the treatment of life-threatening plasmodium falciparum malaria . quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. in the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.

United States - English - NLM (National Library of Medicine)

carilion materials management - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. dosage and administration chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inad

Ireland - English - HPRA (Health Products Regulatory Authority)

lifehealth limited - debrisoquine sulfate - tablets - 10 milligram

United States - English - NLM (National Library of Medicine)

stat rx usa llc - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are not li

United States - English - NLM (National Library of Medicine)

ar scientific inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are

United States - English - NLM (National Library of Medicine)

riconpharma llc - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg